These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35289740)

  • 1. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
    Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
    Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
    J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
    Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 5. Antipseudomonal treatment decisions during CF exacerbation management.
    VanDevanter DR; West NE; Sanders DB; Skalland M; Goss CH; Flume PA; Heltshe SL
    J Cyst Fibros; 2022 Sep; 21(5):753-758. PubMed ID: 35466039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.
    Cogen JD; Onchiri FM; Hamblett NM; Gibson RL; Morgan WJ; Rosenfeld M
    Clin Infect Dis; 2021 Sep; 73(6):987-993. PubMed ID: 33693586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
    J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
    Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.
    Mayer-Hamblett N; Kloster M; Rosenfeld M; Gibson RL; Retsch-Bogart GZ; Emerson J; Thompson V; Ramsey BW
    Clin Infect Dis; 2015 Sep; 61(5):707-15. PubMed ID: 25972024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
    Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
    BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.